POSSIBILITIES TO USE NON-STEROID ANTI-INLAMMATORY DRUGS IN CLINICAL PRACTICE: FOCUS ON NIMESULIDE
https://doi.org/10.21518/2079-701X-2017-17-124-131
Abstract
Currently, nonsteroidal anti-inflammatory drugs (NSAIDs) are a major component of pharmacotherapy of chronic rheumatic pain and are the most commonly prescribed drugs. The cyclooxygenase (COX) – a key enzyme in the synthesis of prostaglandins (PG) mediating the inflammation development – is the target for NSAIDs. The use of NSAIDs is associated with risk of mucosal damage of the gastrointestinal tract (GIT). Its protection is carried out with the participation of PG, the synthesis of which is controlled primarily by COX1, to a lesser extent – by COX2, inducing an inflammatory process. Therefore, one of the most effective measures to prevent disorders of the gastrointestinal tract, was the development of drugs that selectively inhibit the activity of COX2. Such drugs include, in particular, nimesulide (NM Nimesin, Shreya Life Senses). In addition to synthesis of PG-mediated COX2, NM inhibits a number of other mechanisms involved in the development of the inflammatory process. The ability of the NM to act simultaneously on many parts of the inflammatory process allows successfully using it in various inflammation-associated disease. NM was covered in over 200 clinical trials that included more than 90 thousand patients with acute and chronic diseases accompanied by pain syndrome. These authors demonstrated that NM can significantly reduce pain, being not inferior by effectiveness than any of the NSAIDs both: selective and non-selective. At the same the sparing effect of NM on COX1 allows maintaining sufficient concentration of prostanoids, providing physiological protection of the mucosa and reducing the frequency of adverse reactions from the GIT.
About the Authors
Y. A. Olyunin
Nasonova Scientific and Research Institute of Rheumatology
Russian Federation
Russian Federation
MD
N. Y. Nikishina
Nasonova Scientific and Research Institute of Rheumatology
Russian Federation
Russian Federation
PhD in medicine
References
1. Zhu K, Devine A, Dick IM, Prince RL. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine (PhilaPa 1976), 2007 Aug 15, 32(18): 2012-2018.
2. Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S & Sugimoto Y. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochimica et biophysica acta, 2015, 1851: 414-421.
3. Lazarus M, Yoshida K, Coppari R, Bass CE, Mochizuki T, Lowell BB, Saper CB. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci, 2007 Sep, 10(9): 1131-1133.
4. Singh AK, Zajdel J, Mirrasekhian E, Almoosawi N, Frisch I, Klawonn AM, Jaarola M, Fritz M, Engblom D. Prostaglandin-mediated inhibition of serotonin signaling controls the affective component of inflammatory pain. J Clin Invest, 2017 Apr 3, 127(4): 1370-1374. doi: 10.1172/JCI90678.
5. O’Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, O’Farrelly C, Malone KM. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety, 2013 Apr, 30(4): 307-314. doi: 10.1002/da.22087
6. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E, Marlinge E, Tamouza R, Leboyer M. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand, 2014 Mar, 129(3): 163-179. doi: 10.1111/acps.12211.
7. Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci, 2015 May, 36(5): 277-296. doi: 10.1016/j.tips.2015.02.008.
8. Dong L, Zou H, Yuan C, Hong YH, Kuklev DV, Smith WL. Different Fatty Acids Compete with Arachidonic Acid for Binding to the Allosteric or Catalytic Subunits of Cyclooxygenases to Regulate Prostanoid Synthesis. The Journal of biological chemistry, 2016, 291: 4069-4078.
9. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest, 2002 Jul, 110(1): 61-69.
10. Hewett SJ, Bell SC, Hewett JA. Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacology &therapeutics, 2006, 112: 335-357.
11. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология, 2015, (1): 4-23.
12. Олюнин Ю.А. Применение нестероидных противовоспалительных препаратов у больных с высоким кардиоваскулярным риском. Научно-практическая ревматология, 2017, 55(3): 321-323.
13. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet, 1998 Oct, 35(4): 247-274.
14. Bennett A, Villa G. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother, 2000 Jan, 1(2): 277-286.
15. Bianchi M, Ehrlich GE, Facchinetti F et al. Clinical applicationsofnimesulide in pain, arthritic conditions and fever. In: Rainsford KD, editor. Nimesulide. Actions and uses. Basel: Birkhäuser, 2005: 245-313.
16. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivityby central neural plasticity. The journal of pain : official journal of the American Pain Society, 2009, 10: 895-926.
17. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecularmechanisms of pain. Cell, 2009, 139: 267-284.
18. Nicol GD, Klingberg DK, Vasko MR. Prostaglandin E2 increases calciumconductance and stimulates release of substance P in avian sensory neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience, 1992, 12: 1917-1927.
19. Chen L, Yang G, Grosser T. Prostanoids and inflammatory pain. Prostaglandins & other lipid mediators, 2013, 104-105: 58-66.
20. Manicourt DH, Bevilacqua M, Righini V, Famaey JP, DevogelaerJP.Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metal loproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D, 2005, 6(5): 261-271.
21. Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract Suppl, 2002 Jul, (128): 24-29.
22. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation, 2002 Jun, 26(3): 139-142.
23. Kriegel W, Korff KJ, Ehrlich JC, Lehnhardt K, Macciocchi A, Moresino C, PawlowskiC.Doubleblind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract, 2001 Oct, 55(8): 510-514.
24. Omololu B, Alonge TO, Ogunlade SO, Aduroja OO. Double blind clinical trial comparing the safety and efficacy of nimesulide (100mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med, 2005 Apr-Jun, 24(2): 128-133.
25. Herrera JA, González M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am J Ther, 2003 Nov-Dec, 10(6): 468-472.
26. Балабанова Р.М., Белов Б.С., Чичасова Н.В. и др. Эффективность нимесулида при ревматоидном артрите. Фарматека, 2004, 7: 55-58.
27. Марусенко И.М., Везикова Н.Н., Игнатьев В.К. Разумный выбор НПВП при сочетанной патологии: заболеваниях суставов и гипертонической болезни. Лечащий врач, 2004, 02.
28. Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. и др. Эффективность и безопасность монотерапии высокими дозами НПВП при раннем артрите. РМЖ, 2006, 16: 24-29.
29. Сизова Л.В., Багирова Г.Г., Чернышева Т.В. Сравнительный анализ эффективности и безопасности диклофенака и нимесулида у больных ранним ревматоидным артритом. Клиническая медицина, 2009, 10: 62-66.
30. Кудаева Ф.М., Елисеев М.С., Барскова В.Г., Насонова В.А. Сравнение скорости наступления анальгетического и противовоспалительного эффектов различных форм нимесулида и диклофенака натрия при подагрическом артрите. Терапевтический архив, 2007, 5: 35-40.
31. Барскова В.Г., Якунина И.А., Насонова В.А. Применение нимесила при подагрическом артрите. Терапевтический архив, 2003, 5: 60-64.
32. Sacerdote P et al. Cytokine modulation is necessary for efficacious treatment ofexperimental neuropathic pain. Journal of neuroimmune pharmacology : the official journal of the Society on Neuro Immune Pharmacology, 2013, 8: 202-211.
33. Peul WC et al. Surgery versus prolonged conservative treatment for sciatica. The New England journal of medicine, 2007, 356: 2245-2256.
34. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila Pa 1976), 2000 Jun 15, 25(12): 1579-1585.
35. Ilic KV, Sefik-Bukilica M, Jankovic S, VujasinovicStupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo, 2009 Jan-Mar, 61(1): 27-33.
36. Konstantinovic LM, Kanjuh ZM, Milovanovic AN, Cutovic MR, Djurovic AG, Savic VG, Dragin AS, Milovanovic ND. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-controlled study. Photomed Laser Surg, 2010 Aug, 28(4): 553-560. doi: 10.1089/pho.2009.2576.
37. Шихкеримов Р.К. Применение нимесулида в терапии острой боли в нижней части спины. Журнал неврологии и психиатрии им. С.С. Корсакова, 2016, 116(5): 28-32. doi: 10.17116/jnevro20161165128-32.
38. Pulkkinen MO. Is there a rationale for the use of nimesulideinthe treatment of dysmenorrhea? Drugs Today, 2001, 37(SupplB): 31-38.
39. Facchinetti F, Piccinini F, Sgarbi L et al. Nimesulide in thetreatment of primary dysmenorrhea: a double-blind studyversus diclofenac. Drugs Today, 2001, 37(Suppl B): 39-45.
40. Bjarnason I, Bissoli F, Conforti A et al. Adverse reactions andtheir mechanisms from nimesulide. In: Rainsford KD, editor.Nimesulide. Actions and uses. Basel: Birkhäuser, 2005: 315-415.
41. Shah AA, Thjodleifsson B, Murray FE et al. Selective inhibitionof COX-2 in humans is associated with less gastro-intestinalinjury: a comparison of nimesulide and naproxen. Gut, 2001, 48: 339-346.
42. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном использовании нимесулида в реальной клинической практике. РМЖ, 2009, 17, 21: 1466-1471.
43. Laporte JR, Ibáñez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf, 2004, 27(6): 411-420.
Review
For citations:
Olyunin YA, Nikishina NY. POSSIBILITIES TO USE NON-STEROID ANTI-INLAMMATORY DRUGS IN CLINICAL PRACTICE: FOCUS ON NIMESULIDE. Meditsinskiy sovet = Medical Council. 2017;(17):124-131. (In Russ.) https://doi.org/10.21518/2079-701X-2017-17-124-131
Views:
478
Email this article 